Symbiosis Pharmaceutical Services Expands Production Capabilities
Symbiosis Pharmaceutical Services, a leading sterile medicine manufacturing firm based in Stirling, has announced a major expansion with the acquisition of a new facility in the city.
The company has purchased a 20,000 sq/ft building in Stirling’s Castle Business Park, which will be renamed the ‘Bruce Building.’ This significant investment of £1.75 million will double the company’s footprint across its four existing facilities and increase production capacity by 50%.
The expansion is set to safeguard the 130 jobs currently supported by Symbiosis in Stirling while also creating an additional 50 roles in the life sciences sector over the next three years.
The new facility will feature two additional cleanroom-based production lines, further strengthening Symbiosis’ capacity to support its global biotechnology and pharmaceutical clients in the development of innovative medicines and therapies.
Located close to the company’s existing cleanrooms, testing laboratories, and GMP warehouse, the Bruce Building will be equipped with state-of-the-art sterile manufacturing technology.
Symbiosis’ CEO highlighted the strategic importance of this expansion, calling it the next major chapter in the firm’s successful trajectory. They emphasised that the company’s growth has been driven by its ability to maintain organisational and cultural strengths while investing in cutting-edge facilities and infrastructure.
This expansion builds upon Symbiosis’ previous strategic initiatives, including the addition of in-house Quality Control (QC) microbiological and analytical testing services launched last year.
Furthermore, the increased manufacturing capabilities will support Symbiosis’ ambition to further penetrate key markets, particularly in North America and the European Union.
As Symbiosis moves forward with the fit-out of the Bruce Building, the company looks forward to bringing even greater value to its clients and shareholders. This expansion marks another important milestone for the firm as it continues to cement its position as a global leader in sterile medicine manufacturing.
In conclusion, the acquisition and development of the new Bruce Building exemplify Symbiosis’ commitment to both growth and excellence in the life sciences sector.
With a robust strategy in place, increased production capacity, and a clear focus on delivering for its clients, Symbiosis is poised for continued success and innovation in the years to come.
News Credits: Stirling pharmaceutical firm expands city premises to strengthen capacity
Things you may also like: